Ligand-targeted therapeutics in anticancer therapy

By Theresa M. Allen. Nature Reviews. Cancer, 2002

1,584 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/28dbd6ec57d9210a125883f771053a7901ee7db1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Taylor
2. Jun Wu
3. Pranali P. Deshpande
4. N. Bertrand
5. F. Danhier
6. S. Biswas
7. T. Otanicar
8. You Han Bae

Citations in the corpus

• Cancer nanotechnology: opportunities and challenges (2005, background): “There are two general, synergistic goals that should be striven for to increase the efficacy per dose of any therapeutic or imaging contrast formulation: to increase its targeting selectivit”
• Targeted delivery of low molecular drugs using chitosan and its derivatives. (2010, background): “For example, coupling of ligand to carrier can entrap ligands in the particle interior, which may not be available for receptor-binding [122,129].”
• Challenges in Development of Nanoparticle-Based Therapeutics (2012, background): “centration than equal dose of Taxol in tumor xenografts (16).”
• A comprehensive map of molecular drug targets (2016, background): “In this article, we have provided an enhanced and updated perspective on the current diversity of approved drugs and their targets, with a focus on the trends and changes over the past 10 years 7 .”
• Small particles, big impacts: A review of the diverse applications of nanofluids (2013, methodology): “Nanofluids in Medical Applications In the medical field, nanofluids have been used extensively [94], [282–284].”
• Progress of drug-loaded polymeric micelles into clinical studies. (2014, unknown): “expression of the receptors with tumor stage [72].”
• Antibody targeted drugs as cancer therapeutics (2006, background): “Indeed, the moderate cytotoxic potential of these drugs — in combination with the observation that both the amount of cytotoxic drug which can be conjugated to the antibody without reducing its capacity to bind antigen, and the expression of antigens on the tumour cell is limited — posed the problem”